The New VWD Guidelines: Management
Speaker: Veronica Flood, MD
Did you miss the May 26th Wednesday Webinar series? If so click here to listen to Veronica Flood, MD of the Medical College of Wisconsin address the…
Findings from a recently published study in the Journal of Anesthesia suggest that pregnant patients with hemophilia whose factor VIII or IX levels drop below 50% at the time of receiving neuraxial anesthesia are more likely to experience postpartum…
We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on May 27, 2021 07:00 PM Eastern Time . This meeting will discuss NHF business operations and decisions and is open to the public. Join…
The new joint clinical practice guidelines on the diagnosis and management of von Willebrand disease, developed by the American Society of Hematology (ASH), the International Society of Thrombosis and Haemostasis (ISTH), the National Bleeding…
Objective:
Hemophilia A (HA) is an X-linked disorder caused by mutations in the gene encoding Factor VIII protein (FVIII). Gene therapy is increasingly being viewed as a viable treatment option for hemophilia. Herein, long-term…
uniQure recently announced that their commercialization and license agreement with CSL Behring for their investigational hemophilia B gene therapy was finally closed on May 5, 2021 – the agreement had been pending the completion of a series of…